Skip to main content

Table 1 Inclusion and exclusion criteria for the study population

From: Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment

Inclusion criteria
   • aged 6–18 years
   • history of allergic rhinitis for at least 1 year
   • IgE antibodies ≥0.7 kU/l to house dust mite
   • no use of nasal steroids in the month before start of baseline measurements
   • rhinitis symptom score of at least 4 out of 12 during last 3 months
   • signed informed consent
Exclusion criteria
   • severe asthma (requiring 800 mcg budesonide daily or equivalent for other inhaled steroids; or requiring >3 courses of oral prednisone/prednisolone in previous year or required hospital stay for asthma in previous year)
   • sensitization to pets present at home (IgE antibodies ≥0.7 kU/l)
   • planned surgery of nasal cavity
   • having received immunotherapy in past 3 years
   • language barrier
   • contraindications to sublingual immunotherapy (as supplied by the manufacturer)